Return From Pharma Research and Development Innovation
The seventh annual pharmaceutical innovation study, co-produced by the Deloitte Center for Health Solutions in the US and the UK, looks at the challenges the industry faces in generating returns from its R&D investments. The report also highlights key strategies to help increase pipeline value while reducing R&D costs to generate sustainable returns and here are some key points. Key findings The pharmaceutical industry continues to face regulatory and reimbursement hurdles weighing on the research and development (R&D) returns of pharmaceutical firms this year.After reviewing the estimated returns of 12 leading biopharma companies and comparing their performance with four mid-to-large-cap companies, the study finds: Annual projected pharma R&D returns continue to decline to 3.7 percent Peak sales per asset fall 11.4 percent year-over-year since 2010 Costs to bring a product to market stabilize, from $1,576 million in 2015 to $1,539 million in 2016